Clostridium difficile and fluoroquinolones: is there a link?

International Journal of Antimicrobial Agents

Volumn 33, Issue SUPPL. 1, 2009, Pages

  Weiss, Karl ^a  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

Clostridium difficile; Fluoroquinolones

Indexed keywords

8 CHLORO 1 CYCLOPROPYL 7 (2,8 DIAZABICYCLO[4.3.0]NON 8 YL) 6 FLUORO 1,4 DIHYDRO 4 OXO 3 QUINOLINECARBOXYLIC ACID; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; CLINAFLOXACIN; CLINDAMYCIN; ENOXACIN; GATIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; NORFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; GENE MUTATION; HUMAN; INFECTION RISK; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FLUOROQUINOLONES; HUMANS; INFECTION CONTROL;

EID: 62249195493     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(09)70013-5     Document Type: Article

References (40)

1. McDonald L.C., Owings M., and Jernigan D.B. Clostridium difficile in patients discharged from US short-stay hospitals, 1996 2003. Emerg Infect Dis 12 (2006) 409-415
2. Kyne L., Hamel M.B., Polavaram L., and Kelly C.P. Health care costs and mortality associated with nosocomial diarrhoea due to Clostridium difficile. Clin Infect Dis 34 (2002) 346-353
3. Loo V.G., Poirier L., Miller M.A., Oughton M., Libman M.D., Michaud S., et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile- associated diarrhoea with high morbidity and mortality. N Engl J Med 353 (2005) 2442-2449
4. Poutanen S.M., and Simor A.E. Clostridium difficile-associated diarrhoea in adults. CMAJ 171 (2004) 51-58
5. Pepin J., Saheb N., Coulombe M.A., Alary M.E., Corriveau M.P., Authier S., et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhoea: a cohort study during an epidemic in Quebec. Clin Infect Dis 41 (2005) 1254-1260
6. Ehrenpreis E.D., Lievens M.W., and Craig R.M. Clostridium difficile associated diarrhoea after norfloxacin. J Clin Gastroenterol 12 (1990) 188-189
7. Golledge C.L., Carson C., O'Neil G.L., Bowman R.A., and Riley T.V. Ciprofloxacin and Clostridium difficile associated diarrhoea. J Antimicrob Chemother 30 (1992) 141-147
8. Talbot G.H., Cassileth P.A., Paradiso L., Cornea-Corronas R., and Bond L. Oral enoxacin for infection prevention in adults with acute nonlymphocytic leukemia. The enoxacin prophylaxis study group. Antimicrob Agents Chemother 37 (1994) 474-482
9. Clabots C.R., Shanholtzer C.J., Peterson L.R., and Gerding D.N. In vitro activity of efrotomycin, ciprofloxacin, and six other antimicrobials against Clostridium difficile. Diagn Microbiol Infect Dis 6 (1987) 49-52
10. Garcia-Rodriguez J.A., Garcia-Sanchez J.E., Trujillano-Martin I., Garcia-Sanchez E., Garcia-Garcia M.I., and Fresnadillo-Martinez M.J. In vitro activity of BAY Y3118 and nine other antimicrobial agents against anaerobic bacteria. J Chemother 7 (1995) 189-196
11. McDonald L.C., Killgore G.E., Thompson A., Owens Jr. R.C., Kazakova S.V., Sambol S.P., et al. An epidemic, toxin gene variant strain of Clostridium difficile. N Engl J Med 353 (2005) 2433-2441
12. Sanchez-Somolinos M., Alcala L., Pelaez T., Marin M., Martin A., Catalan P., et al. High levels of resistance to fluoroquinolones among Clostridium difficile isolates in a Spanish hospital. Clin Infect Dis 47 (2008) 818-822
13. Drudy D., Quinn T., O'Mahony R., Kyle L., O'Gaora P., and Fanning S. High-level resistance to moxifloxacin and gatifloxacin associated with novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile. J Antimicrob Chemother 58 (2006) 1264-1267
14. Spigaglia P., Barbanti F., Mastrantonio P., Brazier J.S., Barbut F., Delmee M., et al. Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe. J Med Microbiol 57 (2008) 784-789
15. Labbe A.C., Poirier L., MacCannel D., Louie T., Savoie M., Beliveau C., et al. Clostridium difficile in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain. Antimicrob Agents Chemother 52 (2008) 3180-3187
16. Adams D.A., Riggs M.M., and Donskey C.J. Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic Clostridium difficile strains in the cecal contents of mice. Antimicrob Agents Chemother 51 (2007) 2674-2678
17. Gaynes R., Rimland D., Killum E., Lowery H.K., Johnson II T.M., Killgore G., et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 38 (2004) 640-645
18. Ackerman G., Tang-Feldman Y.J., Schauman R., Henderson J.P., Rodloff A.C., Silva J., et al. Antecedent use of fluoroquinolones is associated to moxifloxacin in Clostridium difficile. Clin Microbiol Infect 9 (2003) 526-530
19. Kazarova S.V., Ware K., Baughman B., Bilukha O., Paradis A., Sears S., et al. A hospital outbreak of diarrhoea due to an emerging epidemic strain of Clostridium difficile. Arch Intern Med 166 (2006) 2518-2524
20. McFarland L.V., Claridge J.E., Beneda H.W., and Raugi G.J. Fluoroquinolone use and risk factors for Clostridium difficile associated disease within a Veterans Administration health care system. Clin Infect Dis 45 (2007) 1141-1151
21. Walbrown M.A., Aspinall S.L., Bayliss N.K., Stone R.A., Cunningham F., Squier C.L., et al. Evaluation of Clostridium difficile associated diarrhoea with a drug formulary change in preferred fluoroquinolones. J Manag Care Pharm 14 (2008) 34-40
22. Van der Kooi T.I., Koningstein M., Lindemans A., Notermans D.W., Kuijper E., van den Berg R., et al. Antibiotic use and other risk factors at hospital level for outbreaks with Clostridium difficile PCR ribotype 027. J Med Microbiol 57 (2008) 709-716
23. Dhalla I.A., Mamdani M.M., Simor A.E., Rochon P.A., and Juurlink D.N. Are broad spectrum fluoroquinolones more likely to cause Clostridium difficile associated disease?. Antimicrob Agents Chemother 50 (2006) 3216-3219
24. Muto C.A., Pokrywka M., Shutt K., Mendelsohn A.B., Nouri K., Posey K., et al. A large outbreak of Clostridium difficile associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolones use. Infect Control Hosp Epidemiol 26 (2005) 273-280
25. Biller P., Shank B., Lind L., Brennan M., Tkatch L., Killgore G., et al. Moxifloxacin therapy as a risk factor for Clostridium difficile associated disease during an outbreak: attempts to control a new epidemic strain. Infect Control Hosp Epidemiol 28 (2007) 198-201
26. Valiquette L., Cossette B., Garant M.P., Diab H., and Pepin J. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile associated disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis 45 Suppl 2 (2007) S112-S121
27. Weiss K., Bergeron L., Bernatchez H., Goyette M., Savoie M., and Thirion D. Clostridium difficile associated diarrhoea rates and global antibiotic consumption in five Quebec institutions from 2001 to 2004. Int J Antimicrob Agents 30 (2007) 309-314
28. Zilberberg M.A., Shorr A.F., and Kollef M. Increase in adult Clostridium difficile related hospitalizations and case-fatality rate, United States 2000 2005. Emerg Infect Dis 14 (2008) 929-931
29. Delaney J., Dial S., Barkun A., and Suissa S. Antimicrobial drugs and community acquired Clostridium difficile associated disease, UK. Emerg Infect Dis 13 (2007) 761-763
30. Surveillance des diarrhées associées à Clostridium difficile au Québec bilan du 22 Août 2004 au 18 Août 2007. Québec, Canada: Institut National de Santé Publique du Québec; 2008, p. 22. http://www.inspq.qc.ca/pdf/publications/745_CDifficile_Bilan2004-2007.pdf [accessed 30 December 2008].
31. Weiss K., Boisvert A., Chagnon M., Duchesne C., Habash S., Lepage Y., et al. Clostridium difficile rates from 2002 to 2007: impact of a multi-pronged intervention strategy to control an outbreak situation. Infect Control Hosp Epidemiol 30 (2009) 156-162
32. Muto C.A., Blank M.K., Marsh J.W., Vergis E.N., O'Leary M.M., Shutt K.A., et al. Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive 'bundle' approach. Clin Infect Dis 45 (2007) 1266-1273
33. Surveillance des diarrhées associées à Clostridium difficile au Québec bilan du 20 Août 2006 au 9 Décembre 2006. Québec, Canada: Institut National de Santé Publique du Québec; 2008. http://www.inspq.qc.ca/pdf/publications/620-DiarrheeClostridiumAout-Dec2006.pdf [accessed 30 December 2008].
34. Surveillance des diarrhées associées à Clostridium difficile au Québec bilan du 10 Décembre 2006 au 31 Mars 2007. Québec, Canada: Institut National de Santé Publique du Québec; 2008. http://www.inspq.qc.ca/pdf/publications/680-C.difficileBilan2006-12-10au2007-03-21.pdf [accessed 30 December 2008].
35. Linder J.A., Huang E.S., Steinman M.A., Gonzales R., and Stafford R.S. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med 118 (2005) 259-268
36. Dubberke E.R., Reske K.A., Olsen M.A., McMullen K.M., Mayfield J.L., and McDonald C.M. Evaluation of Clostridium difficile associated disease pressure as a risk factor for C. difficile-associated disease. Arch Intern Med 167 (2007) 1092-1097
37. Deshpande A., Pant C., Jain A., Fraser T.G., and Rolston D.D. Do fluoroquinolones predispose patients to Clostridium difficile associated disease? A review of the evidence. Curr Med Res Opin 24 (2008) 329-333
38. Weiss K. Poor infection control, not fluoroquinolones, likely to be primary cause of Clostridium difficile-associated diarrhoea outbreaks in Quebec. Clin Infect Dis 42 (2006) 725-727
39. Beaulieu M., Thirion D.J.G., Williamson D., and Pichette G. Clostridium difficile-associated diarrhoea outbreaks: the name of the game is isolation and cleaning. Clin Infect Dis 42 (2006) 725
40. Owens R.C., Donskey C.J., Gaynes R.P., Loo V.G., and Muto C.A. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 46 Suppl 1 (2008) S19-S31